News
KPRX
0.5058
-12.72%
-0.0737
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Immutep (NASDAQ:IMMP) stock increased by 15.5% to $2.9 during Wednesday's pre-market session. Syra Health stock rose 14.96% during the session. Sage Therapeutics and Evotec were among the losers in the day's trading.
Benzinga · 20h ago
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Chicken Soup for the Soul (NASDAQ:CSSE) stock is rocketing more than 68% alongside heavy pre-market trading. Tesla’s stock is surging close to 24% following its latest earnings report. Earnings reports, a reverse stock split and more are the biggest pre- market stock movers.
Investorplace · 20h ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
180 Life Sciences (NASDAQ:ATNF) shares moved upwards by 7.4% to $2.04 during Tuesday's after-market session. ABVC BioPharma and Medpace Hldgs stock increased by 5.15%. Fresh2 Group shares fell 12.9% during the session.
Benzinga · 1d ago
Weekly Report: what happened at KPRX last week (0415-0419)?
Weekly Report · 2d ago
Weekly Report: what happened at KPRX last week (0408-0412)?
Weekly Report · 04/15 11:30
Weekly Report: what happened at KPRX last week (0401-0405)?
Weekly Report · 04/08 11:35
Weekly Report: what happened at KPRX last week (0325-0329)?
Weekly Report · 04/01 11:32
Analysts Offer Insights on Healthcare Companies: Altimmune (ALT), Kiora Pharmaceuticals (KPRX) and Actinium Pharmaceuticals (ATNM)
TipRanks · 03/28 11:30
Kiora Pharmaceuticals to Present Additional Data From Its ABACUS-1 Trial Of KIO-301 in Retinitis Pigmentosa At ARVO 2024 Annual Meeting
Benzinga · 03/28 10:51
Analysts Offer Insights on Healthcare Companies: Kiora Pharmaceuticals (KPRX) and Genmab (GMAB)
TipRanks · 03/27 10:30
Kiora Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Kiora Pharmaceuticals Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 47 cents per share. The mean expectation of three analysts was for a loss of 42 cents. Reported revenue was zero; analysts expected zero; shares had risen 14.9% this quarter.
Reuters · 03/25 13:32
Weekly Report: what happened at KPRX last week (0318-0322)?
Weekly Report · 03/25 11:35
Kiora Pharmaceuticals reports FY results
Seeking Alpha · 03/25 11:14
Weekly Report: what happened at KPRX last week (0311-0315)?
Weekly Report · 03/18 11:33
A Look Into Healthcare Sector Value Stocks
A value stock is traditionally defined in terms of how investors are valuing a company's future growth prospects. Low P/E multiples are good indicators that a company is undervalued. The following stocks are considered to be notable value stocks in the healthcare sector. A value stock may need some time to rebound from its undervalued position.
Benzinga · 03/11 14:43
Weekly Report: what happened at KPRX last week (0304-0308)?
Weekly Report · 03/11 11:30
12 Health Care Stocks Moving In Thursday's After-Market Session
Ainos (NASDAQ:AIMD) shares moved upwards by 100.0% to $2.24 during Thursday's after-market session. Unicycive Therapeutics stock rose 8.66% during the day. Talphera and Akili also moved upwards. Losers include Biofrontera and Creative Medical Tech.
Benzinga · 03/07 21:31
Weekly Report: what happened at KPRX last week (0226-0301)?
Weekly Report · 03/04 11:33
Kiora Pharmaceuticals files to sell 76.53M shares of common stock for holders
Healthcare Kiora Pharmaceuticals files to sell 76.53M shares of common stock for holders Feb. 28, 2024. The company filed a prospectus related to the proposed resale of 76. 53 million common shares by the selling stockholders. This prospectus is not an offer to sell these securities.
Seeking Alpha · 02/28 21:54
5 Value Stocks In The Healthcare Sector
A value stock traditionally has a lower price when compared to companies in the same industry. A low price-to-earnings multiple is a good indication that the company is undervalued. Benzinga Insights has selected five notable value stocks in the healthcare sector. The value stocks were selected based on quantified analysis.
Benzinga · 02/26 14:44
More
Webull provides a variety of real-time KPRX stock news. You can receive the latest news about KIORA PHARMACEUTICALS INC through multiple platforms. This information may help you make smarter investment decisions.
About KPRX
Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of orphan retinal diseases. Its pipeline consists of three product candidates, including KIO-301, KIO-104, KIO-101 and KIO-201. Its lead product, KIO-301, is a vision-restoring small molecule that is designed to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). KIO-104 is a next generation, non-steroidal, immuno-modulatory, small-molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH), which is being develop for the treatment of Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases, including rheumatoid arthritis, and as such is termed the Ocular Presentation of Rheumatoid Arthritis and Other Autoimmune Diseases (OPRA+).